Clinical Trial Applications: Filter, Search, and view applications


Clear
Extended search...

Page 10 of 99, showing 5 Applications out of 492 total, starting on record 46, ending on 50

# Protocol No Study Title Investigator(s) & Site(s)

46.

ECCT/24/02/09   pionERA
    This is a Phase III, randomized, open-label multicenter study that will evaluate the efficacy and safety of   giredestrant compared with fulvestrant, both in combination with the investigator's choice of a CDK4/6 inhibitor   (palbociclib, ribociclib or abemaciclib), in participants with estrogen receptor-positive (ER+), human epidermal   growth factor receptor 2-negative (HER2-) advanced breast cancer who have developed resistance to adjuvant   endocrine therapy.   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

47.

ECCT/24/02/08   H06_02TP
    A Phase 2 single-blind, randomized, controlled, single center study to assess the immunogenicity and safety of a 2-dose schedule with GVGH altSonflex1-2-3 vaccine in African infants (H06_02TP)   
Principal Investigator(s)
1. Josphat Kosgei
Site(s) in Kenya
KEMRI WRP CRC KERICHO
 
View

48.

ECCT/24/02/07   CO-SAM
          An adaptive multi-arm trial to improve clinical outcomes among children recovering from complicated severe acute malnutrition (CO-SAM)             
Principal Investigator(s)
1. Benson Singa
Site(s) in Kenya
1. Homabay County Referral hospital (Homa Bay county)
2. Migori County Referral Hospital (Migori county)
3. Mbagathi County Referral Hospital (Nairobi City county)
4. Coast General Teaching and Referral Hospital (Mombasa county)
 
View

49.

ECCT/24/02/06   INAVO122
    A phase III, multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of Inavolisib in combination with Phesgo versus placebo in combination with Phesgo as maintenance therapy after first line induction therapy in participants with PIK3CA‐mutated HER2‐positive locally advanced or metastatic breast cancer   
Principal Investigator(s)
1. Dr Sitna Ali
Site(s) in Kenya
University of Nairobi -Institute of Tropical and Infectious Diseases
 
View

50.

ECCT/24/02/05   Doxo-study
    Pharmacokinetic profiles for Doxorubicin among children with childhood cancer in Kenya.           
Principal Investigator(s)
1. Festus MUIGAI Njunguna
Site(s) in Kenya
MOI UNIVERSITY SCHOOL OF MEDICINE
 
View